Estrella Immunopharma Treats First Patient With Two EB103 Doses in STARLIGHT — 1 Expansion Phase

Estrella Immunopharma reported encouraging initial tolerability in the first patient receiving two EB103 infusions in STARLIGHT-1’s dose-expansion phase for relapsed/refractory B-cell non-Hodgkin’s lymphoma. The patient received infusions three weeks apart, with no treatment-related serious adverse events reported during the first month. Previously reported dose-escalation results showed complete responses in all evaluable high-dose patients, with no treatment-related serious adverse events across nine treated patients. Expansion-cohort data will inform the pivotal trial strategy; additional safety and efficacy results are planned for future reporting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via (Ref. ID: 20261015515780) on October 15, 2026, and is solely responsible for the information contained therein. (C)